Company ProfilePremium

CHA AI Healthkare

Company Profile Analysis

Ticker: 025620.KS차에이아이헬스케어 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
CHA AI Healthkare - Company showcase

Year Founded & Workforce

45 Employees

CHA AI Healthkare logo

CHA AI Healthkare Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

CHA AI Healthkare Overview

CHA AI Healthcare is a small KOSPI-listed company in transition. Its revenue base is still the JAYJUN cosmetics business: sheet masks and skincare sold mainly into China, plus Korea, Japan and other export markets. In 2026, cosmetics accounted for essentially all reported revenue. After CHA Biotech Group took control in October 2025, the company was renamed, appointed group executives to its board, and redefined itself as the listed vehicle for the group's AI and medical-IT ambitions. Its main strategic asset is a minority stake of roughly 36.6% in Kakao Healthcare, acquired in December 2025 alongside affiliate CHA Cares. The stated plan is for the company to act as the executor of hospital IT infrastructure build-out and operation, with Kakao Healthcare supplying AI and data capability for a "Physical AI" in-hospital model. A KRW 52.6bn, five-year supply contract with Japan's Nissho Medical (June 2026) is the first large disclosed commercial anchor. Losses, convertible-bond overhang and dependence on related parties remain defining features.


What the company does today

CHA AI Healthcare currently has two business layers.

1. Legacy operating business: cosmetics (JAYJUN). The company develops, outsources manufacturing of, and sells skincare products under the JAYJUN brand and related brands. Its core category is the sheet mask, especially multi-step premium masks. It has extended into ampoules, creams, sun care, cleansing and sleeping packs. According to Butler.works, cosmetics made up 100% of revenue on a Q2-2026 basis. The company no longer owns a mask factory. In July 2019 it carved its Incheon plant out into a subsidiary, JKM, and sold 100% of JKM to Kolmar's mask subsidiary Kolmask for KRW 32bn (Dealsite, 4-Nov-2019). The business therefore runs an asset-light, brand-owner model with contract manufacturing.

2. New strategic layer: AI healthcare, medical IT and global healthcare. At the 27-Oct-2025 EGM, shareholders approved the name change and added AI medical solutions and global healthcare as business purposes (Asia Economy, 13-Oct-2025; Dealsite, 22-Oct-2025). When the Kakao Healthcare deal closed on 23-Dec-2025, the company said it would develop hospital IT infrastructure build-out and operation as its core growth engine. Under that plan, CHA AI Healthcare executes and operates hospital IT, Kakao Healthcare provides AI and data capabilities, and the company aims for an integrated build-operate-upgrade-data model rather than one-off projects (Asia Economy and Dealsite, 24-Dec-2025). No medical-IT revenue had been separately reported through H1-2026.

Company's own description

No English annual report exists, and the Korean business report (사업보고서) text could not be retrieved directly. The company's public statements describe two aims:

  • To move beyond being a simple beauty company and become a company that combines medical care and healthcare.

  • To become a "total life-care platform" spanning preventive medicine through life-stage-specific health management, using group channels such as CHAUM's power-aging wellness centre and anti-aging/aesthetics services (company statements reported by Asia Economy and The Guru, 13-Oct-2025).

For the cosmetics brand, the post-acquisition philosophy is "Reset Your Skin Algorithm," with "Skin Longevity" as the core brand vision. The brand is being repositioned as an ingredient-led bio-skincare brand (Fintech Times, 1-Sep-2026).

Revenue model

Revenue streamModelStatus (latest available)
Cosmetics product sales (export and domestic)Product sales via distributors, cross-border e-commerce, online B2C and retail (e.g., Daiso, Don Quijote)~100% of revenue (Q2-2026, Butler.works)
Home shopping (TV)Product salesDiscontinued in 2025; the company moved to online B2C to improve profitability (IB Tomato, 29-Jul-2025)
Hospital IT build-out and operationProject plus recurring operation/service (stated intent)Strategy stated Dec-2025. Revenue not separately disclosed through H1-2026.
Nissho Medical long-term supply contractSupply (product/service scope not detailed in sources reviewed)Signed Jun-2026. KRW 52.6bn through 22-Jun-2031.
Equity investment incomeEquity-method share of Kakao Healthcare resultsEquity-method losses recognized (IB Tomato, 25-Jun-2026)

Value-chain position, customers and end markets

Value chain: Brand owner and marketer for cosmetics, with manufacturing outsourced. In healthcare, it is positioned as an intended integrator and operator of hospital IT infrastructure inside the CHA group ecosystem.

Customer types: Overseas distributors and platforms (China, including the JD.com partnership; Japan, via distributor PlanPlus; Southeast Asia, the Americas, Europe), domestic online consumers, and value retail (Daiso). In healthcare, the target customers are hospitals and medical institutions, including CHA group hospitals in 6 countries.

End markets: Mass and premium skincare, with China as the historical core. Medical IT and digital health in Korea and Japan.

Independent characterization

At present, CHA AI Healthcare is better described as a listed holding-and-transition vehicle with a shrinking cosmetics business than as an operating AI-healthcare company. Its consolidated revenue was KRW 7.3bn in FY2025, and cosmetics accounts for all of it. Most of its balance sheet sits in an equity-accounted stake in a loss-making digital-health company, Kakao Healthcare. Most of its strategic options depend on related parties in the CHA group: CHA Cares, CHA Healthcare, CHA Meditech and CHAUM. The 2026 Nissho Medical contract is large relative to the revenue base, at 720% of FY2025 revenue. Its revenue-recognition profile and product scope are not described in the sources reviewed. Investors should treat the AI-healthcare narrative as an option on group synergies, not as an established revenue line.

Strategy

Stated corporate strategy (themes, paraphrased from company statements)

  1. From beauty to medical-healthcare convergence: Move beyond being a beauty company and become a combined medical and healthcare company (EGM announcement, Oct-2025).

  2. Total life-care platform: Combine K-beauty brand strength with AI healthcare across group channels (CHAUM power-aging wellness centre, anti-aging/aesthetics), covering preventive care through life-stage health management.

  3. Hospital IT as the core growth engine: Act as the executor of hospital IT build and operation, and earn recurring revenue through an integrated model of build, operation, upgrade and data use (Dec-2025).

  4. "Physical AI" in hospitals: Embed AI directly into hospital operations, using Kakao Healthcare's AI and data capability.

  5. JAYJUN rebrand: "Reset Your Skin Algorithm" and "Skin Longevity," with an ingredient-led bio-skincare repositioning and an expanded high-efficacy lineup using CHA group technology. The stated aim is to offer ingredient-focused skincare at reasonable prices (Sep-2026).

Initiatives in the last 24 months

DateInitiativeDetailSource
H1-2025Channel restructuringExit from home shopping, move to online B2C, Daiso entryIB Tomato; Asia Economy
Apr-2025ProductPDRN Porcelain Ampoule launchAsia Economy
Jun-2025China channelJD.com collaboration via a Chinese local government linkAsia Economy (12-Jun-2025)
2,025Japan entryDr.Jayjun via PlanPlus and Don QuijoteThe Guru
Jul-2025New business purposes (pre-CHA)Medical, financial-product investment, and overseas equity acquisition purposes added. CB funding plan delayed twice.IB Tomato (29-Jul-2025)
Oct-2025Rename and AI-healthcare purposesEGM approvalsAsia Economy; Dealsite
Oct-2025FinancingKRW 40bn 36th CBIB Tomato
Nov–Dec-2025Kakao Healthcare stakeStrategic collaboration agreement and equity stakeDealsite; Asia Economy
Jun-2026Japan supplyNissho Medical, KRW 52.6bn to 2031Money Today
Sep-2026BrandSkin Longevity rebrandingFintech Times

ESG/sustainability commitments, cost programmes with targets, and medium-term financial targets: None publicly disclosed.

Associate-level target: Kakao Healthcare aimed to reach break-even in Q4-2026 (IB Tomato, 25-Nov-2025). IB Tomato (25-Jun-2026) reported that this timeline had slipped.

Products & Services

Cosmetics (JAYJUN and related brands)

Product / lineDescription and key claimsTarget customer / marketLaunch / latest versionPricing modelSource
Black Water Light (Black 물광) Premium Mask, 3-STEPThree-step format (cleanser, essence, sheet mask in one kit). Flagship product. Sold in 30+ countries; cumulative global shipments of 1.4bn+ sheets.China core; globalOriginal c.2015. 1-step mask-only renewal Jul-2021 ("Black Water Light Hydro Mask").Retail product; price not disclosedThe Guru (Japan launch article); eToday (19-Jul-2021)
Intensive Shining Premium Mask, 3-STEPWhitening and firming mask with eye-area care. 400M+ sheets sold cumulatively. 1-step version "Intensive Blooming Mask" (2021).China; globalOriginal c.2015–16. Renewed 2021.—The Guru; eToday (2021)
Rose Blossom MaskLong-selling mask cited as a China steady-sellerChina——Asia Economy (29-Aug-2025)
JAYJUN Collagen Skin Fit MaskElasticity/firming maskChina——Fintech Times (1-Sep-2026)
Hyaluronic Acid Hydrating Mask and lineHydration mask. 2025 line extensions include sunscreen and cleansing foam.China; Korea onlineLine extension 2025—Fintech Times (2026); Asia Economy (12-Jun-2025)
PDRN Porcelain AmpouleContains 100%-purity PDRN plus multi-hyaluronic acid and ceramide. Positioned for skin-barrier and texture care.Korea; exportApr-2025—Asia Economy (12-Jun-2025)
Okra Phyto Mucin SkincarePlant-mucin skincare lineKorea; exportApr-2021—Asia Economy (9-Sep-2021)
Sleeping packsOvernight mask packs. Sales surged in China c.2021. 3 SKUs in Daiso (2025).China; Korea value retail2021 onwardValue-retail pricing at DaisoeToday (2021); Asia Economy (Jun-2025)
Dr.Jayjun (닥터제이준)Derma/functional brand. Japan-specific reformulation launched via Don Quijote, with PLAZA, LOFT and drugstores planned. 2020 MOU with an acne-specialist clinic.Japan; Korea derma channelJapan launch 2025—The Guru; Asia Economy (30-Oct-2020)
MEZCLAR (메즈클라)BB cream and essence BB. Together with the new hyaluronic-line items, reported cumulative sales of 800k units and KRW 18bn.Korea; exportc.2024–25—Asia Economy (12-Jun-2025)
Genie H (지니에이치)Functional/clean-beauty line cited as a key line in 2025Korea——Hankyung (30-Sep-2025)
Full skincare rangeToners, essences, serums, creams, eye creams, sun care, cleansing, body and hair careGlobalOngoing—Lazada Brand Wiki; Yahoo profile

Historical/other: Jayjun H&B health-functional foods, such as products containing SEANOL® (an ingredient with US FDA NDI notification), including "iSeanol Plus" and "Seanol Q Premium" (eToday, 2-Dec-2019). Medical-aesthetic projects at RF Tech/RF Bio (HA filler, botulinum toxin; 2020).

Planned: A high-efficacy, active-ingredient skincare lineup drawing on CHA Biotech Group technology under the "Skin Longevity" vision (Fintech Times, Sep-2026). Analysts have flagged possible synergy with CHA Meditech's CELLTERMI exosome skin-booster line (Revive EX), which could use JAYJUN's China and Japan distribution. This is speculative, and the group said in Oct-2025 that no concrete plan was ready for disclosure (Dealsite, 28-Oct-2025).

Healthcare / medical IT (stated, pre-revenue)

OfferingDescriptionTarget customerStatusSource
Hospital IT infrastructure build-out and operationCompany to act as the execution entity for hospital IT build and operation, followed by ongoing upgrades and data use (integrated operating model)Hospitals, starting with the CHA group networkStrategy declared Dec-2025. No disclosed revenue.Asia Economy and Dealsite (24-Dec-2025)
"Physical AI" in-hospital business modelAI deployed directly into hospital operations and infrastructure, with Kakao Healthcare supplying AI and data capabilityHospitalsConcept stageSame
Nissho Medical supply programmeKRW 52.6bn long-term supply contract to Jun-2031. Product/service scope not specified in sources reviewed.Nissho Medical (Japan)Signed Jun-2026Money Today via StockHub

Associate's products (Kakao Healthcare — not consolidated)

ProductDescription
PASTAAI-based mobile health-management app
HRS, HaycornMedical data businesses
KareChatHospital concierge service

Source: Dealsite and Kormedi (19-Nov-2025). Kakao Healthcare targeted break-even in Q4-2026 (IB Tomato, 25-Nov-2025).

Financial Narrative

All figures are K-IFRS consolidated, KRW 100M (억원), from Butler.works (DART-derived) unless noted. Blank cells mean the figure was not available in the sources reviewed. Margins, growth and ratios are derived.

Income statement

Revenue CAGR FY2021–FY2025: -22.7% per year (derived: (73/205)^(1/4) − 1).

  • Share counts changed materially (Jun-2025 rights issue, later issuance and CB activity).

Dividends per share: 0 in all years (no dividend; Butler.works shows no dividend yield).

Gross profit and EBITDA: Not publicly available in the sources reviewed.

FY2025 revenue cross-check: The Nissho Medical contract (KRW 52.6bn) was disclosed as 720.05% of the prior year's consolidated revenue. That implies FY2025 revenue of KRW 7.305bn, which matches the KRW 7.3bn reported by Butler.works.

Interim results (FY2026)

Sources: IB Tomato (25-Jun-2026); ETFshopping (from the half-year report filed 12-Aug-2026). H1 figures are derived sums.

Balance sheet

FY2024 source: Digital Today AI disclosure (27-Oct-2025), "latest settlement" consolidated basis.

Other balance-sheet data points:

Cash and equivalents: KRW 5.3bn at 30-Sep-2025 (IB Tomato, 25-Nov-2025).

Convertible bonds: 36th unsecured private CB, KRW 40bn, issued Oct-2025. Convertible into 4,823,926 shares (implied conversion price ≈ KRW 8,292, derived; it may since have been reset under the conversion-price adjustment disclosed 20-Jul-2026).

Implied book equity, latest: About KRW 80bn, derived from market cap of KRW 85.4bn ÷ P/B of 1.05–1.07 (Butler.works, StockHub). This is a large step-up from KRW 29.6bn at FY2024. It is consistent with the Jun-2025 KRW 10bn rights issue, later equity issuance, and the FY2025 and H1-2026 net profits.

Investment in associates: The Kakao Healthcare stake (36.58%) was acquired for about KRW 10bn in purchase price per IB Tomato (21-Nov-2025), plus a separately announced KRW 10bn primary investment (Dealsite, 19-Nov-2025).

Consideration discrepancy: Dealsite and Medigate (19-Nov-2025) state that CHA Cares and CHA AI Healthcare together paid KRW 70bn to Kakao for Kakao Healthcare shares, with CHA AI Healthcare separately investing an additional KRW 10bn. IB Tomato (25-Nov-2025) puts CHA AI Healthcare's share purchase at about KRW 10bn for 36.85%. CHA Cares' consolidated audit report records total consideration for the Kakao Healthcare acquisition of KRW 80bn (IB Tomato, 25-Jun-2026). The split of consideration between CHA Cares and CHA AI Healthcare should be confirmed from DART.

Cash flow

Cash-flow statements were not available in the sources reviewed. The FY2025 financing inflows that are known are:

  • KRW 10bn rights issue to MetaX No.1 (Jun-2025)

  • KRW 40bn 36th CB (Oct-2025)

Ratios

FY2024 ratios derived from the FY2024 figures. Latest ROE TTM is 0.49% per StockHub (Sep-2026).

ROIC, current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle: Not computable from the sources reviewed. EBITDA is negative in all reported years, so net debt/EBITDA and interest coverage are not meaningful.

Commentary on trends, inflections and drivers

Revenue: a structural decline in cosmetics. JAYJUN grew rapidly in China in 2015–2017. Revenue then fell after the THAAD-related Chinese restrictions on Korean consumer brands; the company itself attributed its losses to post-THAAD China weakness (Asia Economy, 12-Aug-2020). By 2020 quarterly revenue was about KRW 10.5bn, down 31% YoY in Q2-2020. Annual revenue then fell from KRW 20.5bn (FY2021) to KRW 6.2bn (FY2022), recovered to KRW 17.0bn (FY2023) and KRW 15.7bn (FY2024), and halved to KRW 7.3bn (FY2025). Management said the FY2025 decline was driven by the deliberate exit from home shopping in favour of online B2C, and said operating profit was being held roughly steady (IB Tomato, 29-Jul-2025). The reported operating loss nevertheless widened from KRW 5.4bn to KRW 7.5bn. That widening probably also reflects deal-related and transition costs in H2-2025, though this is not confirmed.

Profitability: chronic operating losses. The company has had an operating loss in every year from FY2021 to FY2025, totalling KRW 51.1bn on cumulative revenue of KRW 66.7bn (derived). The loss narrowed from FY2021 to FY2024 as costs were cut, then widened in FY2025.

Net income: driven by non-operating items. Net losses exceeded operating losses in FY2021–FY2022 (KRW -39.8bn and -21.7bn). Likely causes are valuation losses on affiliate derivatives and investments, a recurring theme since at least 2020 (Asia Economy, 14-Aug-2020). FY2025 turned to a small net profit of KRW 1.4bn despite an operating loss of KRW 7.5bn. Q2-2026 showed a net profit of KRW 10.4bn against an operating loss of KRW 1.1bn. These swings show that reported earnings currently reflect portfolio and valuation events (Kwanglim, Kakao Healthcare, CB derivatives) more than operations. The specific drivers were not disclosed in the sources reviewed.

Balance sheet: transformed by the 2025 recapitalization. The FY2024 balance sheet was small (assets KRW 38.9bn) with low leverage (liabilities/equity 31%). The KRW 40bn CB and the Kakao Healthcare investment changed both sides of the balance sheet. The CB, its possible derivative liabilities, and the equity-method investment are now the dominant items.

Inflection to watch: The Nissho Medical contract averages about KRW 10.5bn per year over five years if spread evenly (derived: KRW 52.6bn ÷ ~5 years). That is about 1.4x FY2025 revenue. It is the first disclosed revenue source that could change the company's scale. H1-2026 revenue of KRW 4.8bn shows it had not yet been recognized in meaningful volume by mid-year.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Structure

LevelEntityRelationship / stakeSource

Ultimate group

CHA Hospital / CHA Biotech Group

Group parent ecosystem. CHA Biotech (KOSDAQ: 085660) is the listed flagship.

Multiple

Intermediate

CHA Cares Co., Ltd. (차케어스)

CHA Biotech affiliate. Founded 2000. Hospital facility management, hospital contact centres, IT/mobile/digital platforms. FY2025 revenue KRW 67.8bn, operating loss KRW 0.04bn, net loss KRW 13.7bn.

Asia Economy (13-Oct-2025); IB Tomato (25-Jun-2026)

Holding vehicle

MetaX No.1 Investment Partnership

CHA Cares holds 8,538 of 10,002 units (85.4%, Dealsite). Daily Pharm reports 89.0%.

Dealsite (2-Oct-2025); Daily Pharm (Nov-2025)

Listed company

CHA AI Healthcare (025620)

Operating company

—

Associate

Kakao Healthcare Corp.

36.58% held by CHA AI Healthcare at end-2025. CHA Cares 47.03%, Kakao 16.39% at end-2025. Post-second-tranche target: CHA Cares and CHA AI Healthcare combined 43.08%, Kakao 29.99%, external investors 26.93%.

IB Tomato (25-Jun-2026); Dealsite (19-Nov-2025)

Legacy holding

Kwanglim Co., Ltd. (광림)

Jayjun was Kwanglim's largest shareholder (Ssangbangwool-era circular structure). Kwanglim is in delisting proceedings and disposal is expected.

Dealsite (22-Oct-2025)

Legacy subsidiaries

RF Tech / RF Bio; Jayjun H&B (incl. Mongolia entity); US entity

—

Asia Economy (2020); eToday (2019)

Revenue by Segment (KRW) and Segment Margins & Growth (%)

SegmentFY2023FY2024FY2025

Total revenue, consolidated (KRW 100M)

17015773

Operating income, consolidated (KRW 100M)

-102-54-75

Operating margin (%)

-60.0-34.4-102.7

YoY revenue growth (%)

174.2-7.6-53.5

Cosmetics share of revenue (%)

——100

Revenue by Segment (KRW)

Metric (KRW 100M)Q1-2026Q2-2026

Revenue (cosmetics)

1929

Operating income

-24-11

Net income

-46104

Income Statement (KRW) and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW 100M)

2056217015773

Revenue YoY growth (%)

—-69.8174.2-7.6-53.5

Operating income (KRW 100M)

-173-107-102-54-75

Net income (KRW 100M)

-398-217-68-9514

Operating margin (%)

-84.4-172.6-60.0-34.4-102.7

Net margin (%)

-194.1-350.0-40.0-60.519.2

Income Statement (KRW)

Metric (KRW 100M)Q1-2026Q2-2026H1-2026

Revenue

192948

Operating income

-24-11-35

Net income

-4610458

Balance Sheet (KRW) and Margin Analysis (%)

MetricFY2024

Total assets (KRW 100M)

389

Total liabilities (KRW 100M)

93

Total equity (KRW 100M)

296

Liabilities / equity (%)

31.4

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (KRW 100M)

00000

Returns & Leverage Ratios (%)

RatioFY2024FY2025

ROE (%, on year-end equity)

-32.1—

ROA (%, on year-end assets)

-24.4—

ROE TTM latest (%)

—0.49

Revenue by Region (KRW)

Region (KRW 100M)FY2023FY2024FY2025

Total

17015773

Share Price History

DatePriceEventSource

25-Jul-2025

7,300

Close

IB Tomato

30-Sep-2025

11,710

Close (limit-up, CHA acquisition)

Hankyung

1-Oct-2025

15,220

Intraday, 9:30am (second limit-up)

Asia Economy

27-Oct-2025

14,160

Close (EGM day)

Digital Today

22-Jun-2026

5,770

Prior close (derived: 7,500 − 1,730)

Money Today via StockHub

23-Jun-2026

7,500

Intraday limit-up (Nissho contract)

Money Today via StockHub

23-Sep-2026

4,745

Close

StockHub

28-Sep-2026

5,140

Close (+8.9%)

MyDailyByte

Valuation Multiples

MultipleCHA AI HealthcareSource

Market cap (KRW 100M)

854

Butler.works; StockHub

P/E (TTM)

8.27–10.48

StockHub (8.27); Butler.works (10.48). Distorted by non-operating gains.

P/B

1.05–1.07

Butler.works; StockHub

EV/Sales (FY2025)

≈11.7x on market cap/sales; EV not computable

Derived (85.4bn ÷ 7.3bn)

EV/EBITDA

Not meaningful (negative EBITDA)

—

ROE (TTM)

0.49%

StockHub

Rank by market cap in sector

78th of 121 (Household & Personal Products)

StockHub

Capital Markets

ItemStatus

Analyst consensus

None. 0 broker reports (StockHub).

Dividend history / policy

No dividends paid in FY2021–FY2025. No stated policy.

Buyback authorizations

None disclosed. Treasury shares 0.06%.

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt instruments

36th unsecured private CB, KRW 40bn (Oct-2025). Convertible into 4,823,926 shares before adjustments.

Equity issuance (last 18 months)

KRW 10bn rights issue, Jun-2025 (3,241,491 shares).

Analyst Conclusions

Management guidance

No quantitative guidance has been issued. The qualitative direction is:

  • Hospital IT build and operation as the core growth engine

  • A Physical-AI hospital model with Kakao Healthcare

  • Rebuilding JAYJUN as a "Skin Longevity" bio-skincare brand

Consensus expectations

None. There is no sell-side coverage.

Bull case

  1. Contracted step-change in revenue. The Nissho Medical contract (KRW 52.6bn to Jun-2031) is worth about KRW 10.5bn per year if spread evenly. That alone would roughly double to triple the FY2025 revenue base of KRW 7.3bn.

  2. Captive demand from a large healthcare group. CHA group's 77 platforms in 6 countries, its growing smart-hospital IT business, and projects such as the Yongsan senior residence give the company a pipeline of related-party hospital-IT work that standalone peers lack.

  3. Kakao Healthcare optionality. If Kakao Healthcare reaches break-even (its original target was Q4-2026), equity-method losses would stop and the 36.58% stake could be re-rated. The stake was acquired as part of a KRW 100bn funding round.

Bear case

  1. Dilution. Potential overhang equals 79.9% of shares outstanding, including 4.82M CB conversion shares. Conversion-price resets (Jul-2026) increase the share count if the stock stays weak.

  2. No operating proof. Revenue fell 53.5% in FY2025. Operating losses persisted through H1-2026 (KRW -3.5bn). There is no disclosed medical-IT revenue, and synergy had not materialized as of Jun-2026.

  3. Group financial pressure and related-party risk. CHA Biotech's H1-2026 operating loss was KRW 58.9bn, and it is selling subsidiary stakes for liquidity. Minority shareholders of a small listed vehicle are exposed if group needs take priority.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
Q3-2026 report~14-Nov-2026First visible Nissho Medical revenue; operating loss trajectory
Kakao Healthcare results / break-evenQ4-2026 to 2027Equity-method loss size; second-tranche completion
First hospital-IT contract disclosureRollingContract size, counterparty (related party or third party), and recurring share
CB conversions / price resetsRollingShare count; MetaX No.1 stake dilution
Kwanglim stake disposalRollingProceeds versus carrying value
FY2026 business report~Mar-2027Segment disclosure (whether medical IT is separated); auditor opinion
China channel recoveryRollingKorea–China relations; JD.com sales
JAYJUN bio-skincare launches with group actives2026–2027Exosome/PDRN product launches; Japan rollout
Group restructuring (CHA Cares–CHA Healthcare merger or IPO speculation)UncertainEffect on control and related-party flows

Analyst verdict

CHA AI Healthcare is best read as an early-stage restructuring story placed inside a larger group, not as an established AI-healthcare operator. Its reported business is still a small and shrinking cosmetics brand. FY2025 revenue was KRW 7.3bn, with operating losses in every year since at least FY2021, and earnings that swing with valuation and portfolio items rather than operations. The 2025 change of control to CHA Biotech Group added three things it did not have before: a credible controlling shareholder with a multinational hospital network, a 36.6% stake in Kakao Healthcare, and, in June 2026, a KRW 52.6bn five-year supply contract with Nissho Medical that is large relative to the company's size.

The investment question is whether those three assets turn into recurring, profitable revenue faster than dilution and associate losses erode per-share value. At about KRW 85bn of market cap, roughly 1.05x book, and about 12x trailing sales, the market already prices in substantial success, while the share price is near 52-week lows after a roughly 64% fall from post-acquisition peaks. The 36th CB and other potential issuance, together equal to about 80% of shares, are the main constraint on per-share upside.

Disclosure is thin. Segment, geographic, cash-flow and R&D data are not available in public sources, and the scope of the Nissho contract is not described. Any position therefore depends on primary DART documents. Before taking a view, an analyst should confirm three things: the revenue-recognition schedule and margin of the Nissho contract, the carrying value and loss trajectory of the Kakao Healthcare stake, and the current conversion terms of all outstanding CBs.

Verdict: a speculative, event-driven situation with high execution, dilution and governance risk. Q3-2026 results (Nissho revenue start) and the first disclosed hospital-IT contract are the key tests.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NamePositionAppointedBackgroundCompensation

Yoon Kyung-wook (윤경욱)

CEO and inside director

27-Oct-2025

BA Business Administration, Korea University. Former Head of Strategic Planning, CHA Biotech. CEO of CHA Healthcare (led the 2024 consolidation of Singapore Medical Group).

Not publicly disclosed (Korean rules require individual disclosure only above KRW 500M)

Song Jong-guk (송종국)

Inside director

27-Oct-2025

CEO, CHA Cares

—

Kim Seok-jin (김석진)

Inside director

27-Oct-2025

CHA Hospital/Bio Group background

—

Jang Hyung-soo (장형수)

Outside (independent) director

27-Oct-2025

——

Kim Hyun-woo (김현우)

Statutory auditor

27-Oct-2025

——

“—” = not publicly disclosed.

Board & Management Changes

PeriodCEOContext

c.2017–Mar-2019

Lee Jin-hyung (founder), co-CEO with Pan Na from c.2018

F&Republic control era

Mar-2019–Aug-2020

—

Lee resigned and remained a director

Aug-2020–

Lee Jin-hyung (returned)

Cosmetics turnaround mandate

By Jun-2025

Son Sang-hoon (손상훈)

Cited as CEO in Jun-2025 (Asia Economy)

By Aug-2025 – 27-Oct-2025

Jeon Kyung-jae (전경재)

CEO at the Aug-2025 award ceremony. Resigned 27-Oct-2025.

27-Oct-2025 – present

Yoon Kyung-wook

CHA group appointee

Major Shareholders

HolderStakeSource

Treasury shares

0.06%

Butler.works

Competitive Landscape

Key Competitors

CompetitorListingPositioning vs. CHA AI Healthcare

Amorepacific

KOSPI

Diversified K-beauty leader. Far larger scale and owned manufacturing.

LG H&H

KOSPI

Diversified major with a strong China premium portfolio

Mediheal (L&P Cosmetic)

—

Leading Korean sheet-mask brand; direct mask competitor

Abib, Papa Recipe, Leaders Cosmetics (sheet-mask specialists)

Mixed

Direct mask competitors in China and global channels

Able C&C (Missha)

KOSPI

Mass skincare, Japan presence

Clio

KOSDAQ

Colour/skincare; strong Japan and US online

Tonymoly

KOSPI

Value skincare including masks

Korea Kolmar, Cosmax (ODM)

KOSPI

Not brand competitors. Supply-side players that enable low-barrier brand entry and so intensify competition.

Ezcaretech

KOSDAQ

Hospital EMR/HIS and cloud HIS; direct hospital-IT competitor

BIT Computer

KOSDAQ

Hospital information systems

UBcare

KOSDAQ

Clinic EMR and healthcare data

Lunit, Vuno, JLK, Coreline Soft

KOSDAQ

Medical-imaging AI. Adjacent, and expanding into Japan.

Naver Healthcare and large IT services groups (LG CNS, Samsung SDS)

Various

Large-scale hospital digital transformation and AI

Competitor Detail

MetricCHA AI Healthcare

Revenue FY2025 (KRW 100M)

73

Revenue growth FY2025 (%)

-53.5

Operating margin FY2025 (%)

-102.7

Company Snapshot

45

Employees

SWOT Analysis

Strengths

  • Durable China brand recognition: China mask-pack #1 in the Brand of the Year awards for 10 consecutive years (2017–2026), plus the Masterpiece award (Fintech Times, 1-Sep-2026).
  • Proven flagship SKUs: Black Water Light mask with 1.4bn+ cumulative sheets in 30+ countries. Intensive Shining mask with 400M+ sheets (The Guru).
  • Strategic controlling shareholder: CHA Biotech Group, with 77 medical platforms in 6 countries (Kormedi, Nov-2025). Group H1-2026 revenue of KRW 646.1bn (Medigate, Aug-2026).
  • Strategic associate stake: 36.58% of Kakao Healthcare at end-2025 (IB Tomato, Jun-2026). Kakao Healthcare raised KRW 100bn in the transaction (Dealsite, Nov-2025).
  • Large contracted revenue relative to its size: Nissho Medical contract of KRW 52.6bn, equal to 720% of FY2025 revenue, running to Jun-2031 (Money Today, Jun-2026).
  • Asset-light cost base: Plant sold for KRW 32bn in 2019 (Dealsite). Around 45 employees (Morningstar).

Weaknesses

  • Shrinking revenue: FY2025 revenue of KRW 7.3bn, down 53.5% YoY. 4-year CAGR of -22.7% (Butler.works; derived).
  • Chronic operating losses: Operating losses every year FY2021–FY2025, totalling KRW 51.1bn (derived from Butler.works). Q1-2026 operating loss KRW 2.4bn.
  • Earnings quality: Net income is driven by non-operating items. Q2-2026 net profit of KRW 10.4bn against an operating loss of KRW 1.1bn (ETFshopping). FY2025 net profit of KRW 1.4bn against an operating loss of KRW 7.5bn.
  • Thin pre-deal liquidity: Cash of KRW 5.3bn at 30-Sep-2025, below the Kakao Healthcare purchase price (IB Tomato, Nov-2025).
  • Limited disclosure: No IR materials, no segment or geographic detail in public sources, and no sell-side coverage (StockHub shows 0 reports).
  • Frequent control and management changes: Control changed in 2017, 2022, Jun-2025 and Oct-2025. At least three CEOs during 2025 (Son, Jeon, Yoon).

Opportunities

  • Hospital IT build and operation within the CHA network: Stated as the core growth engine (Dec-2025). The group's IT business is already growing at CHA Biotech from smart-hospital projects (Fintech Times, May-2026).
  • Japan scale-up: The Nissho contract plus the Dr.Jayjun retail rollout (Don Quijote, PLAZA, LOFT).
  • China recovery: Leverage from any easing of restrictions on Korean consumer brands, plus the JD.com partnership (Asia Economy, Jun-2025).
  • Exosome and bio-skincare: Global exosome skincare is forecast to grow from about USD 336M (2024) to about USD 663M (2033). CHA Meditech's CELLTERMI line is a possible source of actives (Dealsite, Oct-2025).
  • Kakao Healthcare upside: Kakao Healthcare targeted break-even in Q4-2026. Equity-method losses would turn to gains if it reaches profitability (IB Tomato, Nov-2025).
  • Senior and connected healthcare: CHA Healthcare's Yongsan senior-residence AI/IoT system (occupancy 2029) shows group demand for connected-care infrastructure.

Threats

  • Dilution overhang: The 36th CB converts into 4,823,926 shares. Total potential overhang of 14,548,399 shares equals 79.9% of shares outstanding (IB Tomato, Jun-2026).
  • Associate losses: Kakao Healthcare Q1-2026 operating loss KRW 10.1bn and net loss KRW 10.2bn. Its break-even timing has slipped (IB Tomato, Jun-2026).
  • Group financial strain: CHA Biotech H1-2026 operating loss of KRW 58.9bn, up 77% YoY (Dealsite, Aug-2026). CHA Biotech sold a KRW 200bn stake in CHA Healthcare in Apr-2026 to raise liquidity (Dealsite TV, May-2026).
  • Related-party governance risk: Commentators link the choice of acquisition vehicle to owner-family benefits (Dealsite, Oct-2025). Minority shareholders bear the risk of related-party transactions.
  • Legacy Kwanglim exposure: Kwanglim is in delisting proceedings, so impairment or a forced sale at a discount is possible (Dealsite, Oct-2025).
  • China category competition: Chinese consumers are increasingly price-focused (eToday, 2021). The company exited home shopping because of profitability pressure (2025).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr-2025PDRN Porcelain Ampoule launched Asia Economy (12-Jun-2025)Extends beyond masks into high-value ampoules
H1-2025Home-shopping channel discontinued; move to online B2C IB Tomato (29-Jul-2025)Revenue down, margin focus
H1-2025Daiso nationwide listing (6 SKUs) Asia EconomyDomestic distribution
12-Jun-2025China strategy update: JD.com tie-up; 8th consecutive China award cited Asia EconomyPositioning for possible easing of China restrictions
Jun-2025MetaX No.1 KRW 10bn rights issue (40.36%) DealsiteChange of control after Ssangbangwool Group unwind
25-Jul-2025CB payment date delayed a second time, to September. Shares close at KRW 7,300, about 2x the conversion price. IB Tomato (29-Jul-2025)Funding uncertainty under prior controller
2025Dr.Jayjun Japan launch (Don Quijote) The GuruJapan entry
28-Aug-20259th consecutive China mask-pack #1 award Asia Economy (29-Aug-2025)Brand equity in China
30-Sep-2025CHA Biotech affiliate to acquire control; limit-up to KRW 11,710 HankyungChange of control
1-Oct-2025CHA Cares buys MetaX units for KRW 10.2bn; second limit-up Dealsite; Asia EconomyControl completed
10/13-Oct-2025EGM agenda: rename, AI medical and global healthcare purposes, group nominees Asia Economy; The GuruStrategic pivot
Oct-2025KRW 40bn 36th CB issued IB TomatoFunds the Kakao Healthcare stake; future dilution
21/22-Oct-2025Reports that the Kwanglim stake may be disposed of (Kwanglim in delisting) DealsitePortfolio clean-up and valuation risk
27-Oct-2025EGM approves rename and new board. CEO Jeon resigns; Yoon Kyung-wook becomes CEO. Shares close at KRW 14,160. Digital TodayManagement transition
28-Oct-2025Analyst commentary on CHA Meditech (CELLTERMI exosome) distribution synergy with JAYJUN DealsitePotential cosmetics upside (unconfirmed)
14-Nov-2025Q3-2025 quarterly report filed. Cash KRW 5.3bn at 30-Sep. ETFshopping; IB TomatoLiquidity marker
19/21-Nov-2025Kakao Healthcare stake acquisition announced (Kakao–CHA share swap; KRW 100bn raised by Kakao Healthcare) Dealsite; IB TomatoCore strategic asset
23/24-Dec-2025Kakao Healthcare deal closed. Hospital IT and Physical AI strategy declared. Asia Economy; DealsiteStrategy activation
19-Mar-2026FY2025 annual report: revenue KRW 7.3bn, operating loss KRW 7.5bn, net profit KRW 1.4bn ETFshopping; Butler.worksRevenue down 53%
12-May-2026Q1-2026 report: revenue KRW 1.9bn, operating loss KRW 2.4bn, net loss KRW 4.6bn IB TomatoContinued losses
15-May-2026CHA Biotech Q1: consolidation of CHA AI Healthcare and Kakao Healthcare contributes to group revenue growth Fintech Times; DealsiteGroup integration
22/23-Jun-2026KRW 52.6bn Nissho Medical supply contract (720% of FY2025 revenue; to Jun-2031). Limit-up to KRW 7,500. Money Today via StockHubLargest commercial contract
25-Jun-2026IB Tomato flags equity-method losses from Kakao Healthcare and CB overhang (potential 79.9% of shares)Risk highlight
20-Jul-2026Conversion price adjustment notice filed Butler.worksDilution mechanics
12-Aug-2026H1-2026 report: Q2 revenue KRW 2.9bn, operating loss KRW 1.1bn, net profit KRW 10.4bn ETFshopping; Butler.worksNon-operating gain drove profit
13-Aug-2026CHA Biotech H1 results again cite consolidation of CHA AI Healthcare Medigate; SidaeGroup context
14-Aug-2026Major-holder and executive shareholding reports filed Butler.works–
1-Sep-202610th consecutive China mask-pack #1 award; Masterpiece award; Skin Longevity rebrand Fintech TimesBrand repositioning
28-Sep-2026Shares +8.9% to KRW 5,140 MyDailyByteVolatility near 52-week lows

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment (KRW) (FY2023–FY2025): Total revenue, consolidated fell from KRW 170 in FY2023 to KRW 73 in FY2025.
CHA AI Healthkare — Revenue by Segment (KRW) (FY2023–FY2025)
Series (KRW)FY2023FY2024FY2025
Total revenue, consolidated17015773
Operating income, consolidated-102-54-75

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Asia Economy (core.asiae.co.kr): Rename/EGM (13-Oct-2025); CHA acquisition limit-up (1-Oct-2025); Kakao Healthcare closing (24-Dec-2025); China strategy (12-Jun-2025); 2025 brand award (29-Aug-2025); 2021 brand award (9-Sep-2021); CEO change (12-Aug-2020); Q2-2020 results (14-Aug-2020); Chamjin MOU (30-Oct-2020) · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr · core.asiae.co.kr
  2. The Guru: Rename (Oct-2025) · Japan launch
  3. Hankyung: CHA Biotech to acquire Jayjun (30-Sep-2025) (hankyung.com)
  4. Dealsite: CHA acquisition rationale (2-Oct-2025) · Kwanglim stake (22-Oct-2025) · CHA Meditech synergy (28-Oct-2025) · Kakao Healthcare KRW 100bn (19-Nov-2025) · Deal closing (24-Dec-2025) · Kolmask/JKM (4-Nov-2019) · F&Republic (9-Aug-2018) · CHA Biotech H1-2026 · CHA Healthcare stake sale
  5. IB Tomato / NewsTomato: Kakao Healthcare stake (25-Nov-2025) · CB/goodwill burden (25-Jun-2026) · CB delay (29-Jul-2025)
  6. Digital Today: CEO Yoon Kyung-wook (27-Oct-2025) (digitaltoday.co.kr)
  7. StockHub: Nissho Medical contract (23-Jun-2026) · Stock data
  8. Butler.works: 5-year financials, filings list (butler.works)
  9. ETFshopping: Quarterly results and filing dates (etfshopping.com)
  10. MyDailyByte: Price and news · 10th award
  11. Fintech Times: 10th consecutive award (1-Sep-2026) · CHA Biotech Q1-2026
  12. Daily Pharm: Kakao–CHA swap · dailypharm.com · SMG consolidation · CHA Biotech Q2-2026
  13. Kormedi: CHA Group becomes Kakao Healthcare's largest shareholder (kormedi.com)
  14. Medigate News: CHA Biotech H1-2026 · Kakao Healthcare investment
  15. eToday: Global expansion (21-Nov-2019) · Mongolia (2-Dec-2019) · Mask renewal (19-Jul-2021)
  16. Morningstar AU profile · Yahoo Finance profile · CB Insights · Lazada Brand Wiki
  17. MTN: Korean medical AI in Japan (15-Sep-2026) (news.mtn.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.